CA color bar

CA Live w circleR 2018 v2

CureAccelerator Live! for Rare Diseases 

Virtual: June 11, 2020 from 3:30-5:30pm ET

CureAccelerator Live! is our philanthropic pitch event where up to 5 PIs are the finalists presenting their clinical repurposing trials for up to $50,000 in funding and attendees select the winning project.


Watch the 3-minute highlights video HERE; watch the entire event HERE!


CA logo graphic only


Repurposing a Nutraceutical in Myeloproliferative Neoplasms to Improve Disease Markers and Symptoms

UCI Health CFCCC NCI lockup1 CALrare20 fleischman Angela Fleischman, MD, PhD

Fleishchman pitch opening small



Contact us to learn more about any of these ready-to-fund clinical repurposing trials.  Help us match our funding being raised now!

UCDavisEyeCenter logo  CALrare20 Park     Susanna Park, MD, PhD

Bone Marrow Stem Cell Therapy for Vision Loss

An 8-patient clinical trial investigating the safety and efficacy of autologous stem cell transplant to treat vision loss from the hereditary condition, retinitis pigmentosa.  CLICK HERE to watch Dr. Park's pitch her project and HERE to read her project poster.


UofMI Signature Vertical     CALrare20 Phillips    Tycel Phillips, MD

Repurposing Venetoclax to Improve Patient Response in Mantle Cell Lymphoma

Evaluating the long-term efficacy of adding the chronic lymphocytic leukemia drug venetoclax to lenalidomide plus rituximab treatment in 28 patients with newly diagnosed mantle cell lymphoma, to improve patient outcomes.  CLICK HERE to watch Dr. Phillips pitch his project and HERE to read his project poster.


stanford comboCALrare20 Sakamoto  Kathleen Sakamoto, MD, PhD

Niclosamide for the Treatment of Pediatric Acute Myeloid Leukemia 

Determining the safety and efficacy of combining the generic anti-tapeworm drug niclosamide with standard chemotherapy in 16 children with relapsed/refractory acute myeloid leukemia.  CLICK HERE to watch Dr. Sakamoto pitch her project and HERE to read her project poster.


CHOP new Apr2020 CALrare20 Seif   Alix Seif, MD, MPH

Preventing Relapse After Bone Marrow Transplant in Pediatric Acute Lymphoblastic Leukemia  with a Personalized Treatment 

Determining the feasibility and safety of identifying 30 children with acute lymphoblastic leukemia (ALL) at risk of relapse following a bone marrow transplant and treating them with either blinatumomab (used to treat relapsed ALL), daratumumab (approved for multiple myeloma), or standard of care to prevent relapse.  CLICK HERE to watch Dr. Seif pitch her project and HERE to read her project poster.


CureAccelerator Live! for Rare Diseases was part of the two-day, virtual

GG ODC Rare Drug Development Logo 1 2

on June 11 - 12, 2020, in partnership with

global genes logo registered 1 2

The Rare Drug Development Symposium is a partnership of Penn Medicine Orphan Disease Center and Global Genes



Cures Within Reach is proud to hold this event in support of our Rare Diseases Community.  In addition, we are grateful to our industry partners for their support:

                                                    Horizon Logo Full Color RGB M01 UPDATED 2019                    RRD LOGO tagline TM CMYK Black


Funding support for the winning project comes from: 

GPP Logo

Additional support for CureAccelerator Live! for Rare Diseases comes from:  

JHF Logo


Questions? Email Director of Scientific Affairs: Dr. Clare Thibodeaux at

CA logo graphic only


Click here to sign up for our eNewsletter today!

Please include your Full Name* and Email Address*


If the link above doesn't work, please contact our Admin support at with your Full Name and Email Address to sign up!


Cures Within Reach

134 N. LaSalle, #1130
Chicago, IL 60602

All funds donated to Cures Within Reach may be tax deductible for federal income tax purposes. 

Partnership for Cures DBA Cures Within Reach is recognized by the IRS as a 501(c)3 tax-exempt not-for-profit organization, tax ID 20-3620169.


Sunday the 27th. Copyright 2018 Cures Within Reach.